Biolase Inc has a consensus price target of $3.56, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from Ascendiant Capital, Benchmark, and Lake Street on April 1, 2024, March 22, 2024, and May 31, 2023. With an average price target of $1.6 between Ascendiant Capital, Benchmark, and Lake Street, there's an implied 1032.34% upside for Biolase Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/01/2024 | BIOL | Buy Now | Biolase | $0.14 | 2730.86% | Ascendiant Capital | Edward Woo | $15 → $4 | Maintains | Buy | Get Alert |
03/22/2024 | BIOL | Buy Now | Biolase | $0.14 | 183.09% | Benchmark | Bruce Jackson | $2.5 → $0.4 | Maintains | Speculative Buy | Get Alert |
05/31/2023 | BIOL | Buy Now | Biolase | $0.14 | 183.09% | Lake Street | Frank Takkinen | $150 → $40 | Maintains | Buy | Get Alert |
03/29/2023 | BIOL | Buy Now | Biolase | $0.14 | 607.71% | Maxim Group | Anthony Vendetti | $500 → $100 | Maintains | Buy | Get Alert |
03/29/2023 | BIOL | Buy Now | Biolase | $0.14 | 1315.43% | Benchmark | Bruce Jackson | → $200 | Reiterates | → Speculative Buy | Get Alert |
01/20/2023 | BIOL | Buy Now | Biolase | $0.14 | 961.57% | Lake Street | Frank Takkinen | → $150 | Assumes | → Buy | Get Alert |
05/20/2022 | BIOL | Buy Now | Biolase | $0.14 | 8392.57% | Lake Street | Kyle Bauser | → $1200 | Initiates | → Buy | Get Alert |
The latest price target for Biolase (NASDAQ: BIOL) was reported by Ascendiant Capital on April 1, 2024. The analyst firm set a price target for $4.00 expecting BIOL to rise to within 12 months (a possible 2730.86% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Biolase (NASDAQ: BIOL) was provided by Ascendiant Capital, and Biolase maintained their buy rating.
There is no last upgrade for Biolase.
There is no last downgrade for Biolase.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biolase, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biolase was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
While ratings are subjective and will change, the latest Biolase (BIOL) rating was a maintained with a price target of $15.00 to $4.00. The current price Biolase (BIOL) is trading at is $0.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.